Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8227675 | International Journal of Radiation Oncology*Biology*Physics | 2012 | 9 Pages |
Abstract
At a mean follow-up of 36 months, dose-escalated chemotherapy-IMRT at DL2 has so far been safe to deliver. In this study, DL2 delivered high rates of locoregional control, progression-free survival, and organ preservation and has been selected as the experimental arm in a Cancer Research UK Phase III study.
Keywords
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Aisha B. F.R.C.R., Shreerang A. F.R.C.R., M. Teresa F.R.C.R., Catharine Ph.D., A. Margaret M.Sc., Suzanne Ph.D., Yolanda M.Sc., Roger M.Sc., Mary M.Sc., Jennifer Dip. Nursing, Robyn Dip. Nursing, Kate L. F.R.C.R., Kevin J. F.R.C.R.,